Cardiometabolic & kidneyMeta-analysis
Cardiovascular and renal outcomes of GLP-1 receptor agonists in type 2 diabetes mellitus: a systematic review and meta-analysis
- systematic review and meta-analysis
- random-effects model
Authors' conclusion
GLP-1RAs are associated with improved cardiovascular outcomes in patients with T2DM. These findings support current guideline recommendations and highlight their cardioprotective benefits beyond glycaemic control in patients with T2DM.
Study context
- Population
- Patients with type 2 diabetes mellitus (T2DM) in randomized controlled trials comparing GLP-1RAs with placebo
- Participants
- 83,004 Twenty randomized controlled trials (RCTs)
- Comparison
- GLP-1RAs compared to placebo
Pooled result
Major adverse cardiovascular events
Relative risk
0.87
95% CI 0.83–0.92
GLP-1RAs vs placebo
RR 0.87 (95% CI 0.83–0.92)
As reported in the abstract
Further pooled results
| Outcome | RR (95% CI) | |
|---|---|---|
| All-cause death | 0.89 (0.84–0.93) | |
| Cardiovascular death | 0.88 (0.81–0.94) | |
| Myocardial infarction | 0.87 (0.79–0.96) | |
| Stroke | 0.88 (0.81–0.96) | |
| Composite renal outcome | 0.80 (0.73–0.88) | |
| Heart failure hospitalizations · trend of reduction without reaching statistical significance | 0.93 (0.85–1.01) | |
| Coronary revascularization · trend of reduction without reaching statistical significance | 0.87 (0.74–1.01) | |
| 0.512Relative risk (log scale) |
Original publication
Cardiovascular and renal outcomes of GLP-1 receptor agonists in type 2 diabetes mellitus: a systematic review and meta-analysis. Eur Heart J Qual Care Clin Outcomes. Published 16 May 2026. doi:10.1093/ehjqcco/qcag079
Summarised from the published abstract; every number is checked against it